Formycon AG (FYB.F)
| Previous close | 85.90 |
| Open | 85.30 |
| Bid | 85.90 x 30000 |
| Ask | 86.80 x 30000 |
| Day's range | 85.30 - 86.70 |
| 52-week range | 42.50 - 88.00 |
| Volume | |
| Avg. volume | 364 |
| Market cap | 1.308B |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.75 |
- EQS Group
Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study
DGAP-News: Formycon AG / Key word(s): Study results/StudyFormycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study 16.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // August 16, 2022 Formycon’s Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study VESPUCCI study demonstrates the comparable efficacy of FYB2
- EQS Group
U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2
DGAP-News: Formycon AG / Key word(s): Regulatory Approval/Product LaunchU.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2 03.08.2022 / 09:00 The issuer is solely responsible for the content of this announcement. Press Release // August 3, 2022 U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2 CIMERLI™
- EQS Group
Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
Formycon AG / Key word(s): Regulatory Approval/Product LaunchFormycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®203-Aug-2022 / 07:50 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Publication of insider information in accordance with Article 17 of the Regula
